Health Economics›Acute myeloid leukemia›Consolidation after upfront therapy

Consolidation after upfront therapy

Acute myeloid leukemia · 35 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Azacitidine and Gemtuzumab ozogamicin Variant #01	—	R 59 517	8d	—	—	—	—	—
Cytarabine, Daunorubicin, Gemtuzumab ozogamicin Variant #01	—	R 57 910	—	—	—	—	—	—
HiDAC and Midostaurin Variant #01	FLT3	R 51 391	28d	—	—	—	—	—
Cytarabine, Idarubicin, Sorafenib Variant #01	—	R 30 380	42d	—	—	—	—	—
IDAC and Sorafenib Variant #01	FLT3	R 28 660	42d	—	—	—	—	—
Cytarabine and Daunorubicin Variant #03	—	R 26 542	—	—	—	—	—	—
Amsacrine and HiDAC Variant #01 Partial	—	R 26 364	—	—	—	—	—	—
High-dose Cytarabine monotherapy (HiDAC) Variant #01	—	R 26 364	—	—	60.0 mo	—	—	—
Busulfan and Fludarabine, then allo HSCT Variant #08	—	R 19 257	—	~9.0 mo	—	—	—	2
Azacitidine monotherapy Variant #01	—	R 18 699	28d	—	~8.7 mo	—	—	11
4i+7 Variant #01	—	R 17 665	—	—	—	—	—	—
CIA Variant #01 Partial	—	R 17 528	5d	—	—	—	—	—
HiDAC and ATRA Variant #01	NPM1	R 16 123	—	—	—	—	—	—
HAM Variant #01	—	R 13 754	—	—	—	—	—	—
HiDAC and Quizartinib Variant #01 Partial	FLT3	R 13 182	—	—	—	—	—	—
HiDAC and G-CSF Variant #01	—	R 13 182	35d	—	—	—	—	—
4d+7 Variant #01	—	R 12 259	—	—	—	—	—	—
Cytarabine and Etoposide (CYVE) Variant #06	—	R 11 761	—	—	~9.2 mo	—	—	—
Etoposide and Mitoxantrone Variant #01	—	R 11 505	—	—	—	—	—	—
5+2i Variant #01	—	R 11 478	5d	—	—	—	—	—
Clofarabine and LoDAC/Decitabine Variant #01 Partial	—	R 11 028	49d	—	—	—	—	—
Busulfan and Cyclophosphamide Variant #01	—	R 7 711	—	—	—	—	—	—
IC and Norethandrolone/6-MP, MTX, Norethandrolone Variant #01 Partial	—	R 6 594	60d	—	—	—	—	—
5+2d Variant #01	—	R 5 983	5d	—	—	—	—	—
Cytarabine and Idarubicin Variant #01	—	R 4 599	30d	—	—	—	—	—
Intermediate-dose Cytarabine monotherapy (IDAC) Variant #01	—	R 3 662	28d	—	~7.6 mo	—	—	1
CLARA Variant #01 Partial	—	R 3 662	35d	—	—	—	—	—
Cyclophosphamide and TBI, then allo HSCT Variant #01	—	R 1 176	—	—	—	—	—	—
Cytarabine monotherapy Variant #01	—	R 366	30d	—	—	—	—	—
Fludarabine and TBI, then allo HSCT N/A - secondary systemic drug	—	R 0	—	—	—	—	—	—
Cytarabine, Idarubicin, Vorinostat N/A - secondary systemic drug	—	R 0	28d	—	—	—	—	—
CPX-351 monotherapy Variant #01 Partial	—	—	49d	—	~9.3 mo	—	—	1
Fludarabine, Busulfan, ATG, then allo HSCT Partial	—	—	—	—	—	—	—	—
BuCy Partial	—	—	—	—	—	—	—	—
Low-dose TBI, then allo HSCT Variant #01 Partial	—	—	—	—	—	—	—	—

35 of 35 regimens shown